NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2024 Update

Summary

NovoCure Ltd (NovoCure) is an oncology company with a focus on the development and commercialization of novel delivery systems for the treatment of brain, thoracic and abdomen cancers. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. The company markets TTF-based delivery systems, Optune Lua for the treatment of malignant pleural mesothelioma; and Optune Gio for the treatment of glioblastoma. The products are indicated in combination with standard chemotherapies. The company has operations in five regions, namely, United States, Germany, Japan, Greater China, and Other international markets. NovoCure is headquartered in Saint Helier, Jersey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


NovoCure Ltd Company Overview
NovoCure Ltd Company Snapshot
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd – Pipeline Analysis Overview
Business Description
NovoCure Ltd - Key Facts
NovoCure Ltd - Major Products and Services
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
Maxpoint Treatment Planning Software
Maxpoint Treatment Planning Software Product Overview
Next Gen Field Generator
Next Gen Field Generator Product Overview
NovoTTF-100M System
NovoTTF-100M System Product Overview
NovoTTF-100M System Clinical Trial
NovoTTF-200A - Small Cell Lung Cancer
NovoTTF-200A - Small Cell Lung Cancer Product Overview
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Product Overview
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Clinical Trial
NovoTTF-200T - Pancreatic Cancer
NovoTTF-200T - Pancreatic Cancer Product Overview
NovoTTF-200T - Pancreatic Cancer Clinical Trial
Optune - Brain Metastasis
Optune - Brain Metastasis Product Overview
Optune - Brain Metastasis Clinical Trial
Optune - Breast Cancer
Optune - Breast Cancer Product Overview
Optune - Cervical Cancer
Optune - Cervical Cancer Product Overview
Optune - Colorectal Carcinoma
Optune - Colorectal Carcinoma Product Overview
Optune - Ependymoma
Optune - Ependymoma Product Overview
Optune - Gastric Adenocarcinoma
Optune - Gastric Adenocarcinoma Product Overview
Optune - Gastric Adenocarcinoma Clinical Trial
Optune - Gliosarcoma
Optune - Gliosarcoma Product Overview
Optune - Liver Cancer
Optune - Liver Cancer Product Overview
Optune - Malignant Melanoma
Optune - Malignant Melanoma Product Overview
Optune - Medulloblastoma
Optune - Medulloblastoma Product Overview
Optune - Meningioma
Optune - Meningioma Product Overview
Optune - Mesothelioma
Optune - Mesothelioma Product Overview
Optune - Mesothelioma Clinical Trial
Optune - Non-Small Cell Lung Cancer
Optune - Non-Small Cell Lung Cancer Product Overview
Optune - Non-Small Cell Lung Cancer Clinical Trial
Optune - Ovarian Cancer
Optune - Ovarian Cancer Product Overview
Optune - Pancreatic Cancer
Optune - Pancreatic Cancer Product Overview
Optune - Pancreatic Cancer Clinical Trial
Optune - Pediatric Glioma
Optune - Pediatric Glioma Product Overview
Optune - Pediatric Glioma Clinical Trial
Optune - Renal Adenocarcinoma
Optune - Renal Adenocarcinoma Product Overview
Optune - Small Cell Lung Cancer
Optune - Small Cell Lung Cancer Product Overview
Optune - Torso Array
Optune - Torso Array Product Overview
Optune - Torso Array Clinical Trial
Optune - Urinary Transitional Cell Carcinoma
Optune - Urinary Transitional Cell Carcinoma Product Overview
Optune Plus Bevacizumab - Recurrent Glioblastoma
Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
Optune With Marizomib And Temozolomide - Glioblastoma
Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
Optune With Pembrolizumab And Temozolomide
Optune With Pembrolizumab And Temozolomide Product Overview
Optune With Pembrolizumab And Temozolomide Clinical Trial
NovoCure Ltd - Key Competitors
NovoCure Ltd - Key Employees
NovoCure Ltd - Key Employee Biographies
NovoCure Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
NovoCure Ltd, Recent Developments
Aug 17, 2024: NovoCure Receives Additional FDA 510(k) Clearance for Optune Lua (NovoTTF-100L System)
Aug 14, 2024: Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
Jul 25, 2024: Novocure Reports Second Quarter 2024 Financial Results
Jun 03, 2024: METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
May 23, 2024: TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Apr 24, 2024: Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Apr 05, 2024: Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024
Mar 27, 2024: Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Jan 18, 2024: Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Jan 09, 2024: Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Indication
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd, Key Facts
NovoCure Ltd, Major Products and Services
NovoCure Ltd Number of Pipeline Products by Development Stage
NovoCure Ltd Pipeline Products Summary by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Ongoing Clinical Trials Summary
Maxpoint Treatment Planning Software - Product Status
Maxpoint Treatment Planning Software - Product Description
Next Gen Field Generator - Product Status
Next Gen Field Generator - Product Description
NovoTTF-100M System - Product Status
NovoTTF-100M System - Product Description
NovoTTF-100M System - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
NovoTTF-100M System - Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain Metastases
NovoTTF-200A - Small Cell Lung Cancer - Product Status
NovoTTF-200A - Small Cell Lung Cancer - Product Description
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Status
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Description
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Phase 0 Trial of Pre-operative Tumor Treating Fields in Patients with Resectable Lung Cancer
NovoTTF-200T - Pancreatic Cancer - Product Status
NovoTTF-200T - Pancreatic Cancer - Product Description
NovoTTF-200T - Pancreatic Cancer - A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Optune - Brain Metastasis - Product Status
Optune - Brain Metastasis - Product Description
Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Optune - Breast Cancer - Product Status
Optune - Breast Cancer - Product Description
Optune - Cervical Cancer - Product Status
Optune - Cervical Cancer - Product Description
Optune - Colorectal Carcinoma - Product Status
Optune - Colorectal Carcinoma - Product Description
Optune - Ependymoma - Product Status
Optune - Ependymoma - Product Description
Optune - Gastric Adenocarcinoma - Product Status
Optune - Gastric Adenocarcinoma - Product Description
Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
Optune - Gliosarcoma - Product Status
Optune - Gliosarcoma - Product Description
Optune - Liver Cancer - Product Status
Optune - Liver Cancer - Product Description
Optune - Malignant Melanoma - Product Status
Optune - Malignant Melanoma - Product Description
Optune - Medulloblastoma - Product Status
Optune - Medulloblastoma - Product Description
Optune - Meningioma - Product Status
Optune - Meningioma - Product Description
Optune - Mesothelioma - Product Status
Optune - Mesothelioma - Product Description
Optune - Mesothelioma - TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
Optune - Non-Small Cell Lung Cancer - Product Status
Optune - Non-Small Cell Lung Cancer - Product Description
Optune - Non-Small Cell Lung Cancer - EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Optune - Ovarian Cancer - Product Status
Optune - Ovarian Cancer - Product Description
Optune - Pancreatic Cancer - Product Status
Optune - Pancreatic Cancer - Product Description
Optune - Pancreatic Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Optune - Pediatric Glioma - Product Status
Optune - Pediatric Glioma - Product Description
Optune - Pediatric Glioma - Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
Optune - Pediatric Glioma - HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma
Optune - Renal Adenocarcinoma - Product Status
Optune - Renal Adenocarcinoma - Product Description
Optune - Small Cell Lung Cancer - Product Status
Optune - Small Cell Lung Cancer - Product Description
Optune - Torso Array - Product Status
Optune - Torso Array - Product Description
Optune - Torso Array - A Clinical Usability Study of Torso Array to Improve Patient Comfort for All Torso and Abdominal Indications
Optune - Urinary Transitional Cell Carcinoma - Product Status
Optune - Urinary Transitional Cell Carcinoma - Product Description
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
Optune With Pembrolizumab And Temozolomide - Product Status
Optune With Pembrolizumab And Temozolomide - Product Description
Optune With Pembrolizumab And Temozolomide - Phase II, Single Arm, Historically Controlled Study Testing the Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
NovoCure Ltd, Key Employees
NovoCure Ltd, Key Employee Biographies
NovoCure Ltd, Subsidiaries
Glossary
List of Figures
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings